Merck Names Ken Frazier President
This article was originally published in The Pink Sheet Daily
Executive Summary
The promotion moves Frazier one step closer to becoming CEO and Chairman when Dick Clark retires as expected next year.
You may also be interested in...
Merck Financials Remain On Track, Despite Generic Cozaar, Health Reform
In buying Schering-Plough for $41.1 billion in March 2009, Merck aimed to lower its risk and build its product portfolio in the face of looming patent, reimbursement and pipeline challenges. A year after announcing plans for the merger, first-quarter results suggest that the company is keeping its promises
Merck Financials Remain On Track, Despite Generic Cozaar, Health Reform
In buying Schering-Plough for $41.1 billion in March 2009, Merck aimed to lower its risk and build its product portfolio in the face of looming patent, reimbursement and pipeline challenges. A year after announcing plans for the merger, first-quarter results suggest that the company is keeping its promises
Merck Financial Targets Remain On Track, Despite Generic Cozaar, Health Care Reform
Key brands contributed strong performance, Schering integration is progressing smoothly without interrupting the business' momentum.